- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ben Jones Outlines Policies Having the Biggest Impact on Cancer Care Delivery
The proposals that will have the biggest impact on community oncology and cancer care delivery in general are those that are still pending, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
The proposals that will have the biggest impact on community oncology and cancer care delivery in general are those that are still pending, explained Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health.
Transcript
What are some recent policies that are having the biggest impact on cancer care delivery?
There’s been a number of policies that have really taken shape over the last 18 months that have significantly transformed community oncology and cancer care in general. One of them is around site of service parity; that is establishing a level of reimbursement field for certain services on a go forward basis and even in the last round of rulemaking for clinic office visits. There have been changes to 340B that have had an impact to community cancer care and cancer care in general.
But by in large, the biggest proposals are those that are pending. The president has released his drug pricing blueprint that had contained a number of changes, seismic shifts, in policy for Part B reform. They include step therapy, a relaxing of protected classes, but also a new international index model, the International Pricing Index Model, that would completely change the way that Part B drugs are acquired, stored, and administered to patients. I really think this could lead to a lot of disruption in access to timely care for practices across the country.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
